Compound ID | 2883
CF-370
Synonym(s): CF370
Class: Bacteriophage and/or bacteriophage-derived product
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, and Stenotrophomonas maltophilia; disrupts integrity of outer membrane and hydrolyses peptidoglycan |
| Description: | Engineered lysin with fused outer-membrane permeabilizing peptide; shows synergistic effect with bata-lactams, aminoglycosides, quinolones, or polymyxins |
| Institute where first reported: | Contrafect |
| Year first mentioned: | 2023 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive as of 2024 |
| Reason Dropped: | Reported to proceed to Phase I in late 2023 but Contrafect declared bankruptcy on December 2023 |
| External links: | |
| Citation: | https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae027/7608873?login=true |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.